



## ASX ANNOUNCEMENT

24 December 2019

### NOTICE GIVEN UNDER SECTION 708A(5)(e) OF CORPORATIONS ACT

---

Cann Group Limited (**Cann**) (ASX: CAN) gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) that:

- (a) Cann has on 24 December 2019 issued 550,278 fully paid ordinary shares by way of a placement to Commonwealth Scientific and Industrial Research Organisation (**CSIRO**), a sophisticated investor, as settlement of an invoice for services rendered without disclosure to the investor under Part 6D.2 of the *Corporations Act*; and
- (b) as at the date of this notice:
  - (1) Cann has complied with the provisions of Chapter 2M of the *Corporations Act* as they apply to Cann;
  - (2) Cann has complied with section 674 of the *Corporations Act*; and
  - (3) there is no information that is “excluded information” within the meaning of sections 708A(7) and 708A(8) of the *Corporations Act* that is required to be set out in this notice under section 708A(6)(e) of the *Corporations Act*.

Signed for and on behalf of Cann Group Limited.

Geraldine Farrell  
**Company Secretary**

Peter Crock  
CEO  
Cann Group Limited  
+61 3 9095 7088  
[contact@canngrouplimited.com](mailto:contact@canngrouplimited.com)

Clive Fanning  
Head of Investor Relations  
Cann Group Limited  
+61 498 000 762  
[clive.fanning@canngrouplimited.com](mailto:clive.fanning@canngrouplimited.com)

Matthew Wright  
NWR Communications  
+61 451 896 420  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

#### **About Cann Group**

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia. The company has established research and cultivation facilities in Melbourne and is striving to provide access to medicinal cannabis for Australian patients. Cann Group has executed collaboration agreements that will enable it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. It was issued with Australia’s first medicinal cannabis research licence in February 2017, in addition to Australia’s first medicinal cannabis cultivation licence in March 2017. Aurora Cannabis Inc – one of Canada’s largest listed medicinal cannabis companies – is a cornerstone investor in Cann, with a 22.5% shareholding.